NUMD Nu-Med Plus, Inc.
Gold and Silver Ores · OTC · SEC CIK 1543637 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY17.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-650.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets3,529.1%
Debt / equity—
Current ratio0.03x
Interest coverage-6.77x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-94.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — |
| SG&A expense | $8,073 | $4,832 | $5,469 | $5,705 | $6,037 | $9,467 | — | $5,984 |
| Operating income | -$22,556 | -$13,151 | -$10,419 | -$18,700 | -$9,294 | -$17,417 | — | -$20,579 |
| Interest expense | $2,774 | $2,727 | $1,246 | $1,233 | $1,261 | $1,260 | — | $1,247 |
| Pretax income | $19,670 | — | -$11,665 | — | -$10,555 | -$18,677 | — | — |
| Income tax | $0 | $0 | $0 | — | — | — | — | — |
| Net income | $19,670 | -$15,878 | -$11,665 | -$19,933 | -$10,555 | -$18,677 | -$17,287 | -$21,826 |
| EBITDA | -$22,556 | -$13,151 | -$10,419 | -$18,700 | — | — | — | — |
| EPS (basic) | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | 0.00 |
| EPS (diluted) | 0.00 | — | 0.00 | — | — | 0.00 | — | 0.00 |
| Weighted avg. shares (diluted) | 83.55M | 83.55M | 83.55M | 83.55M | — | 81.35M | — | 83.55M |
| Balance sheet | ||||||||
| Cash & equivalents | $5,409 | $4,284 | $863 | $2,373 | $2,373 | $4,041 | — | $6,356 |
| Current assets | $12,909 | $7,184 | — | — | $9,373 | $6,841 | — | $9,016 |
| PP&E, net | $0 | $0 | — | — | — | — | — | — |
| Total assets | $12,909 | $7,184 | — | — | $9,373 | $6,841 | — | $9,016 |
| Current liabilities | $280,395 | $294,340 | — | — | $224,469 | $211,382 | — | $177,593 |
| Long-term debt | $0 | $0 | — | — | — | — | — | — |
| Total debt | $0 | $0 | — | — | — | — | — | — |
| Total liabilities | $280,395 | $294,340 | — | — | $224,469 | $211,382 | — | $177,593 |
| Shareholders' equity | -$267,486 | -$287,156 | -$246,694 | -$235,029 | -$215,096 | -$204,541 | -$185,864 | -$168,577 |
| Net debt | -$5,409 | -$4,284 | — | — | — | — | — | — |
| Shares outstanding | 83.55M | 83.55M | — | — | 83.55M | 83.55M | — | 83.55M |
| Cash flow statement | ||||||||
| Operating cash flow | $1,125 | -$6,377 | -$1,510 | $0 | -$1,668 | — | — | -$450 |
| Investing cash flow | $0 | $0 | $0 | $0 | — | — | — | — |
| Financing cash flow | $0 | $10,000 | $0 | $0 | — | — | — | — |
| Depreciation & amortization | $0 | $0 | $0 | $0 | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 56 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.